CR20210301A - Ácidos nucleicos para inhibir la expresión de LPA en una célula - Google Patents

Ácidos nucleicos para inhibir la expresión de LPA en una célula

Info

Publication number
CR20210301A
CR20210301A CR20210301A CR20210301A CR20210301A CR 20210301 A CR20210301 A CR 20210301A CR 20210301 A CR20210301 A CR 20210301A CR 20210301 A CR20210301 A CR 20210301A CR 20210301 A CR20210301 A CR 20210301A
Authority
CR
Costa Rica
Prior art keywords
expression
cell
pathology
disorder
inhibit
Prior art date
Application number
CR20210301A
Other languages
English (en)
Inventor
Judith Hauptmann
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
Lucas Bethge
Christian Frauendorf
David Anthony Rider
Adrien Weingaertner
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/081106 external-priority patent/WO2019092283A1/en
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of CR20210301A publication Critical patent/CR20210301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a productos y composiciones y sus usos. En particular, la invención se refiere a productos de ácido nucleico que interfieren con la expresión del gen LPA o inhiben su expresión, preferentemente para uso como tratamiento, prevención o reducción del riesgo de sufrir enfermedad cardiovascular tal como cardiopatía coronaria o estenosis de la aorta o accidente cardiovascular o cualquier otro trastorno, patología o síndrome relacionado con niveles elevados de partículas Lp(a).
CR20210301A 2018-11-13 2019-11-13 Ácidos nucleicos para inhibir la expresión de LPA en una célula CR20210301A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2018/081106 WO2019092283A1 (en) 2017-11-13 2018-11-13 Nucleic acids for inhibiting expression of lpa in a cell
EP19174466 2019-05-14
PCT/EP2019/081158 WO2020099476A1 (en) 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
CR20210301A true CR20210301A (es) 2021-09-16

Family

ID=66554180

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210301A CR20210301A (es) 2018-11-13 2019-11-13 Ácidos nucleicos para inhibir la expresión de LPA en una célula

Country Status (29)

Country Link
US (2) US20220002722A1 (es)
EP (2) EP3880818B1 (es)
JP (1) JP7245328B2 (es)
KR (1) KR102553386B1 (es)
CN (1) CN113227372A (es)
BR (1) BR112021009213A2 (es)
CA (1) CA3119239C (es)
CL (1) CL2021001225A1 (es)
CO (1) CO2021007372A2 (es)
CR (1) CR20210301A (es)
DK (1) DK3880818T3 (es)
EA (1) EA202190895A1 (es)
ES (1) ES2932295T3 (es)
FI (1) FI3880818T3 (es)
HR (1) HRP20221358T1 (es)
HU (1) HUE060703T2 (es)
IL (1) IL283159A (es)
LT (1) LT3880818T (es)
MA (1) MA58208B1 (es)
MX (1) MX2021005590A (es)
PE (1) PE20211282A1 (es)
PH (1) PH12021550801A1 (es)
PL (1) PL3880818T3 (es)
PT (1) PT3880818T (es)
RS (1) RS63778B1 (es)
SA (1) SA521421963B1 (es)
SG (1) SG11202103882QA (es)
SI (1) SI3880818T1 (es)
WO (1) WO2020099476A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3607069T3 (pl) * 2017-04-05 2023-03-06 Silence Therapeutics Gmbh Produkty i kompozycje
ES2938193T3 (es) 2017-11-13 2023-04-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresión de LPA en una célula
PE20211282A1 (es) 2018-11-13 2021-07-19 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula
JP2023545502A (ja) 2020-10-16 2023-10-30 サノフイ リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
CA3229020A1 (en) * 2021-09-14 2023-03-23 Stella Khan Treatment of cardiovascular disease
IL314872A (en) 2022-02-09 2024-10-01 Silence Therapeutics Gmbh Therapeutic inhibition of LPA expression
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024013334A1 (en) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of agt in a cell
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024151937A1 (en) * 2023-01-13 2024-07-18 Eli Lilly And Company Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US20060160759A1 (en) 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
WO2009151644A2 (en) 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
EP3011028B1 (en) * 2013-06-21 2019-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
PL3607069T3 (pl) 2017-04-05 2023-03-06 Silence Therapeutics Gmbh Produkty i kompozycje
CA3118327A1 (en) * 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
ES2938193T3 (es) * 2017-11-13 2023-04-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresión de LPA en una célula
PE20211282A1 (es) 2018-11-13 2021-07-19 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula

Also Published As

Publication number Publication date
JP7245328B2 (ja) 2023-03-23
LT3880818T (lt) 2022-12-27
KR20210095878A (ko) 2021-08-03
AU2019380628A1 (en) 2021-05-20
FI3880818T3 (fi) 2022-12-15
CL2021001225A1 (es) 2021-12-24
MA58208B1 (fr) 2022-12-30
PL3880818T3 (pl) 2023-01-23
KR102553386B1 (ko) 2023-07-07
PE20211282A1 (es) 2021-07-19
PH12021550801A1 (en) 2021-10-04
EP4219712A3 (en) 2023-11-22
CA3119239A1 (en) 2020-05-22
WO2020099476A1 (en) 2020-05-22
US11499153B2 (en) 2022-11-15
IL283159A (en) 2021-06-30
EA202190895A1 (ru) 2021-08-10
CN113227372A (zh) 2021-08-06
JP2022507282A (ja) 2022-01-18
SG11202103882QA (en) 2021-05-28
BR112021009213A2 (pt) 2021-08-10
MX2021005590A (es) 2023-01-24
US20220170016A1 (en) 2022-06-02
SI3880818T1 (sl) 2023-01-31
US20220002722A1 (en) 2022-01-06
EP3880818B1 (en) 2022-09-28
DK3880818T3 (da) 2022-12-05
EP4219712A2 (en) 2023-08-02
HUE060703T2 (hu) 2023-04-28
HRP20221358T1 (hr) 2022-12-23
PT3880818T (pt) 2022-12-06
ES2932295T3 (es) 2023-01-17
RS63778B1 (sr) 2022-12-30
SA521421963B1 (ar) 2024-03-25
EP3880818A1 (en) 2021-09-22
CA3119239C (en) 2024-06-04
CO2021007372A2 (es) 2021-07-09

Similar Documents

Publication Publication Date Title
CR20210301A (es) Ácidos nucleicos para inhibir la expresión de LPA en una célula
ZA202003371B (en) Nucleic acids for inhibiting expression of lpa in a cell
MX2018005096A (es) Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
PH12017500977A1 (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2015006407A (es) Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido.
MY188292A (en) Binding proteins specific for lox1 and uses thereof
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2021003845A (es) Composiciones para reducir el acido urico serico.
MX2017003897A (es) Derivados estabilizados de adrenomedulina y uso de los mismos.
PH12017500795B1 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
EP3483271A3 (en) Products and compositions
BR112020012668A8 (pt) Composição para o tratamento de um paciente com doença respiratória associada a inflamações crônicas e método de produção e utilização da composição
MD3880818T2 (ro) Acizi nucleici pentru inhibarea expresei LPA într-o celulă
MX2008009161A (es) Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
Douglas 25 years of the TQM Journal
Oki et al. B39 INTERVENTIONAL PULMONARY MEDICINE: RECENT ADVANCES: Therapeutic Rigid Bronchoscopy For Patients With Airway Stenosis Due To Small Cell Lung Cancer
MX2022002993A (es) Rebamipida para usarse en la prevencion y/o tratamiento de la rigidez arterial.
Gharaee-Kermani et al. A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Resveratrol Inhibits The Stimulatory Effects Of Tgfß1 And Cxcl12 On Idiopathic Pulmonary Fibrosis Primary Lung Fibroblast Proliferation And Myofibroblast Phenoconversion
Tanner Cochrane review: Deep venous incompetence (DVI)
UA105536U (uk) Спосіб лікування діастолічної дисфункції серця у хворих на цукровий діабет 2 типу, які перенесли не-q-інфаркт міокарда
UA107447C2 (uk) Спосіб оцінки ефективності лікування пропранололом хворих на ішемічну хворобу серця з стенокардією та артеріальною гіпертензією з порушенням діастолічної функції лівого шлуночка по "гіпертрофічному" типу